Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027625 · ClinicalTrials.gov registry record · Phase 1
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00027625 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
The verdict
NCT00027625, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining gefitinib with temozolomide in treating patients who have malignant primary glioma.
Interventions
- DRUG temozolomide
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01-28 |
| Est. Completion | 2005-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027625
The ClinicalTrials.gov registry entry for NCT00027625 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which temozolomide is the first listed.
NCT00027625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027625 about?
NCT00027625 is a clinical study titled "Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma". RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib with chemotherapy may kill more tumor cel...
What is the current status of trial NCT00027625?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-01-28. Estimated completion is 2005-11-01.
What interventions are being tested in trial NCT00027625?
The interventions under investigation include: temozolomide (DRUG), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00027625?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.